Speculative small caps drove the week, with Tasman Resources, Solis Minerals and Lithium Energy leading the board after funding, drilling and asset sale updates. At the other end, ASX Ltd and Arafura Rare Earths fell hard as investors reacted to higher costs and fresh equity issuance.
- Tasman Resources, Solis Minerals and Lithium Energy led weekly gains
- Gold, lithium, rare earths and copper explorers dominated the risers
- Capital raisings split the market, backing growth for some stocks but hurting others
- Travel, healthcare and industrial names added support with strong results and deal activity
- ASX Ltd was the standout large-cap faller after lifting expense and capex guidance
Tasman Resources (ASX:TAS) topped the weekly movers with a 73.17% jump after raising $4.05 million and adding Adam Turnbull to the board ahead of more drilling. Solis Minerals (ASX:SLM) climbed 41.18% as it set June drilling for Brazilian lithium targets. Lithium Energy (ASX:LEL) added 34.43% after outlining a new graphite exploration target and a proposed $20 million sale of its graphite assets. Those gains showed where buyers were willing to take risk: early-stage projects with a clear near-term event.
Resources stayed in control
Mining names filled much of the winners list. Tolu Minerals (ASX:TOK) rose 7.12% after reporting new high-grade gold veins near Tolukuma and pushing ahead with a large drilling program. White Cliff Minerals (ASX:WCN) still fell 18.75% despite extending copper mineralisation at Rae, a sign that good drill news alone was not always enough after earlier enthusiasm. Strickland Metals (ASX:STK) gained 15.00% when its Gradina gold resource grew by 50 per cent. Vulcan Energy (ASX:VUL) rose 14.33% after reaching financial close on its €2.2 billion Lionheart project, because investors now have more confidence the build will go ahead. Elsewhere in the same part of the market, Ionic Rare Earths (ASX:IXR) surged 22.22% on a US supply deal tied to magnet materials, while West Cobar Metals (ASX:WC1) also jumped 22.22% on scandium recovery results. Encounter Resources (ASX:ENR) gained 26.53% after signing a niobium battery MoU. Buyers kept chasing stocks where the news pointed to a product that could be sold, not just a rock in the ground. That same logic helped Havilah Resources (ASX:HAV), which secured a $105 million payment from Sandfire, and Brightstar Resources (ASX:BTR), which approved development of its Goldfields project even though its shares slipped 1.39% for the week.Placements and project funding split opinion
Fresh money was a major theme, but the share price reaction depended on how the market judged the trade-off. Arafura Rare Earths (ASX:ARU) dropped 14.52% after a $350 million placement to fund Nolans construction. Investors liked the cash, but the new shares meant existing holders owned a smaller slice of the company. Qoria (ASX:QOR) moved up 3.45% as shareholders moved closer to approving its merger with Aura, which is paired with a US$100 million raise and an ASX listing. In that case, buyers focused on the chance to combine two software businesses and add new capital at the same time. Develop Global (ASX:DVP) rose 9.29% after strong drilling at Pioneer Dome set up a June final investment decision. Greatland Resources (ASX:GGP) added 4.68% after receiving key environmental approvals for Havieron, another step needed before a board can approve mine spending. When a company moves from study work to approved construction, investors often care because the project starts to look more real. The risk is simple too: costs can still rise, and promised timelines can still slip.Healthcare and tech found buyers again
Noxopharm (ASX:NOX) rallied 34.37% after new immune system data for its Sofra platform. Investors bought the stock because the update suggested the drug technology may have broader value in cancer treatment. Elsight (ASX:ELS) climbed 31.66% on a US$2 million follow-on order from a US public safety customer, which mattered because it showed repeat demand rather than a one-off trial. Neuren Pharmaceuticals (ASX:NEU) advanced 6.36% as DAYBUE royalties kept rising and its Phase 3 trial progressed. In plain terms, royalties mean cash coming in from a drug already selling, while Phase 3 is the late-stage testing often needed before wider approval. Fisher & Paykel Healthcare (ASX:FPH) gained 12.73% after posting stronger revenue, profit and a higher dividend. Aroa Biosurgery (ASX:ARX) rose 11.20% as sales beat guidance. Blackpearl Group (ASX:BPG) added 5.45% after doubling annual recurring revenue, which is a simple way to track contracted software income. Pacific Edge (ASX:PEB) was more mixed. Its shares still rose 7.14%, even after a large loss, because a draft Medicare policy offered a possible route back to US test reimbursement.Bigger names moved on costs, deals and guidance
Among the larger companies, ASX Ltd (ASX:ASX) slumped 22.30% after warning that FY27 expenses could rise 18 to 21 per cent and capex could reach $200 million. Investors cared because higher costs can cut profit, even if revenue stays solid. Web Travel Group (ASX:WEB) rose 12.50% on record FY26 numbers and a strong cash balance. Flight Centre Travel Group (ASX:FLT) added 9.08% after its investor day pointed to AI-led savings and growth in cruise, luxury and corporate travel. Charter Hall Group (ASX:CHC) gained 5.43% after lifting earnings guidance on the back of strong equity inflows. Infratil (ASX:IFT) edged up 0.46% as data centre and renewable energy assets kept growing. Champion Iron (ASX:CIA) fell 9.74% despite a profit rise and project progress, while Endeavour Group (ASX:EDV) lost 6.49% after laying out cost cuts and a new investment plan. In both cases, investors appeared to want faster proof that the strategy would turn into stronger returns. Take the week as a whole and one pattern stands out. Sustained buying stayed with stocks that offered a near-term catalyst such as drilling, approvals, contracts or financing. Some names that gapped up on fresh news kept climbing as more buyers came in. Others gave back early gains when the announcement raised new questions about dilution, timing or whether the first burst of excitement had run too far.Bottom Line?
The next stretch looks event-heavy. Investors now have June decisions, drilling starts, feasibility work, court and shareholder meetings, and major project funding milestones to test whether this week’s strongest moves can hold.
Questions in the middle?
- Will Arafura’s fresh capital be enough to shift attention from dilution to Nolans construction progress?
- Can the best-performing explorers turn drilling excitement into larger resources or mine approvals in coming weeks?
- After ASX’s sharp fall, will investors accept higher spending as the cost of fixing systems and meeting regulators?